John S. Bradley (United States of America)

Rady Children’s Hospital-San Diego
Professor Bradley completed his paediatric infectious diseases training at Stanford University in 1981 and spends his time divided between clinical care, clinical research and national policy. His clinical research priorities are the development of effective therapy for neonates, infants and children with infections caused by multi-drug resistant Gram-negative bacilli and MRSA, working closely with pharmacologists and microbiologists, using pharmacodynamic/ pharmacokinetic modeling techniques for dose optimisation. He is chair of the Scientific Review Committee for a large paediatric clinical trials consortium, I-ACT, working with academic centres, the Food and Drug Administration and the healthcare industry to study new tests, therapies and vaccines for COVID19. He is also on the FDA’s Advisors and Consultants Staff. Professor Bradley was the lead author on the first national guidelines for the treatment of pneumonia in children and is one of the members of the CDClead Influenza Guidelines Committee , as well as the co-chair of the new Pediatric Bone and Joint Infection Guidelines that are currently being written. Additionally, he is the editor and a co-author for “Nelson’s Pediatric Antimicrobial Therapy,” a book on the treatment of paediatric infections

Presenter of 3 Presentations

Welcome and introduction: addressing the unmet need in paediatric patients (ID 2109)

Targeting MDR Gram-negative infections: an alternative treatment for paediatric patients (ID 2111)

Moderator of 1 Session

Session Type
Fri, 28.05.2021
Session Time
14:15 - 15:45
Industry Symposia
Session Description


Session Description:

Managing infectious diseases in children involves many of the therapeutic principles used to treat adults. However, the paediatric patient population faces unique challenges including a different risk factor profile compared with adults, limited treatment options and distinct pharmacokinetic parameters. These challenges not only drive the need to reimagine the future of patient care, but also provide opportunities for innovation and breakthrough treatments.

Join our global panel as they introduce recent therapeutic advances in the management of bacterial infections for the paediatric patient. They will discuss how these therapies may address the current and anticipated burden of unmet need and consider their potential to improve patient outcomes. This session will include a live panel discussion in which our esteemed faculty will share their knowledge, insights and experience in managing this vulnerable population.

Session Icon
Live Session